|
Prof Robert Weinberg explains what he presented at NCRI 2010 regarding the mechanisms of cancer cells disseminate within the body and the formation of metastases in distant tissues. Although this process appears to be complex, activation of just one normally latent embryonic programme known as epithelial-mesenchymal transition (EMT), is sufficient for cancer cells to disseminate. Prof Weinberg speaks about the stages necessary for cancer cells to change from primary tumour cells to a form that can migrate to distant sites and discusses the role of mesenchymal cells and the signalling between mesenchymal and carcinoma cells. Prof Weinberg explains how the EMT can convert epithelial carcinoma cells into cancer stem cells with the ability to initiate new tumours and outlines his hope that we will eventually be able to reverse this process. Prof Weinberg concludes by discussing the session he will be chairing on the recruitment of stromal cells by carcinomas.
|
Video Length: 0
Date Found: January 14, 2011
Date Produced:
|
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured Content
Featuring websites that enhance the internet user’s experience.
|